Chemotherapeutic Approaches for Targeting Cell Death Pathways
Tóm tắt
After completing this course, the reader will be able to: List the multiple cell death pathways that are activated in response to chemotherapeutic agents.Identify signaling molecules involved and morphological changes that occur in the different types of cell death pathways.Describe mechanisms targeted by novel chemotherapeutic agents.
Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com
For several decades, apoptosis has taken center stage as the principal mechanism of programmed cell death in mammalian tissues. It also has been increasingly noted that conventional chemotherapeutic agents not only elicit apoptosis but other forms of nonapoptotic death such as necrosis, autophagy, mitotic catastrophe, and senescence. This review presents background on the signaling pathways involved in the different cell death outcomes. A re-examination of what we know about chemotherapy-induced death is vitally important in light of new understanding of nonapoptotic cell death signaling pathways. If we can precisely activate or inhibit molecules that mediate the diversity of cell death outcomes, perhaps we can succeed in more effective and less toxic chemotherapeutic regimens.
Từ khóa
Tài liệu tham khảo
Brown, 2005, The role of apoptosis in cancer development and treatment response, Nat Rev Cancer, 5, 231, 10.1038/nrc1560
Okada, 2004, Pathways of apoptotic and non-apoptotic death in tumour cells, Nat Rev Cancer, 4, 592, 10.1038/nrc1412
Dimri, 2005, What has senescence got to do with cancer?, Cancer Cell, 7, 505, 10.1016/j.ccr.2005.05.025
Lum, 2005, Autophagy in metazoans: cell survival in the land of plenty, Nat Rev Mol Cell Biol, 6, 439, 10.1038/nrm1660
Castedo, 2004, Cell death by mitotic catastrophe: a molecular definition, Oncogene, 23, 2825, 10.1038/sj.onc.1207528
Yuan, 2003, Diversity in the mechanisms of neuronal cell death, Neuron, 40, 401, 10.1016/S0896-6273(03)00601-9
Smogorzewska, 2002, Different telomere damage signaling pathways in human and mouse cells, EMBO J, 21, 4338, 10.1093/emboj/cdf433
Degterev, 2005, Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury, Nat Chem Biol, 1, 112, 10.1038/nchembio711
Broker, 2005, Cell death independent of caspases: a review, Clin Cancer Res, 11, 3155, 10.1158/1078-0432.CCR-04-2223
Chipuk, 2005, Do inducers of apoptosis trigger caspase-independent cell death?, Nat Rev Mol Cell Biol, 6, 268, 10.1038/nrm1573
Fink, 2005, Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells, Infect Immun, 73, 1907, 10.1128/IAI.73.4.1907-1916.2005
Kroemer, 2005, Classification of cell death: recommendations of the Nomenclature Committee on Cell Death, Cell Death Differ, 12, 1463, 10.1038/sj.cdd.4401724
Kerr, 1972, Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics, Br J Cancer, 26, 239, 10.1038/bjc.1972.33
Cory, 2002, The Bcl2 family: regulators of the cellular life-or-death switch, Nat Rev Cancer, 2, 647, 10.1038/nrc883
Lindsten, 2000, The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues, Mol Cell, 6, 1389, 10.1016/S1097-2765(00)00136-2
Wei, 2001, Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death, Science, 292, 727, 10.1126/science.1059108
Suzuki, 2000, Structure of Bax: coregulation of dimer formation and intracellular localization, Cell, 103, 645, 10.1016/S0092-8674(00)00167-7
Scorrano, 2003, BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis, Science, 300, 135, 10.1126/science.1081208
Willis, 2005, Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins, Genes Dev, 19, 1294, 10.1101/gad.1304105
Du, 2000, Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition, Cell, 102, 33, 10.1016/S0092-8674(00)00008-8
Suzuki, 2001, A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death, Mol Cell, 8, 613, 10.1016/S1097-2765(01)00341-0
Verhagen, 2000, Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins, Cell, 102, 43, 10.1016/S0092-8674(00)00009-X
El-Deiry, 2003, The role of p53 in chemosensitivity and radiosensitivity, Oncogene, 22, 7486, 10.1038/sj.onc.1206949
Leu, 2004, Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex, Nat Cell Biol, 6, 443, 10.1038/ncb1123
Mihara, 2003, p53 has a direct apoptogenic role at the mitochondria, Mol Cell, 11, 577, 10.1016/S1097-2765(03)00050-9
Locksley, 2001, The TNF and TNF receptor superfamilies: integrating mammalian biology, Cell, 104, 487, 10.1016/S0092-8674(01)00237-9
LeBlanc, 2003, Apo2L/TRAIL and its death and decoy receptors, Cell Death Differ, 10, 66, 10.1038/sj.cdd.4401187
Chinnaiyan, 1995, FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis, Cell, 81, 505, 10.1016/0092-8674(95)90071-3
Kischkel, 1995, Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor, EMBO J, 14, 5579, 10.1002/j.1460-2075.1995.tb00245.x
Donepudi, 2003, Insights into the regulatory mechanism for caspase-8 activation, Mol Cell, 11, 543, 10.1016/S1097-2765(03)00059-5
Boatright, 2003, A unified model for apical caspase activation, Mol Cell, 11, 529, 10.1016/S1097-2765(03)00051-0
Li, 1998, Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis, Cell, 94, 491, 10.1016/S0092-8674(00)81590-1
Luo, 1998, Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors, Cell, 94, 481, 10.1016/S0092-8674(00)81589-5
Bidere, 2006, Genetic disorders of programmed cell death in the immune system, Annu Rev Immunol, 24, 321, 10.1146/annurev.immunol.24.021605.090513
Brunner, 1995, Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas, Nature, 373, 441, 10.1038/373441a0
Dhein, 1995, Autocrine T-cell suicide mediated by APO-1/(Fas/CD95), Nature, 373, 438, 10.1038/373438a0
Ju, 1995, Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation, Nature, 373, 444, 10.1038/373444a0
Zheng, 1995, Induction of apoptosis in mature T cells by tumour necrosis factor, Nature, 377, 348, 10.1038/377348a0
Janssen, 2005, CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death, Nature, 434, 88, 10.1038/nature03337
Barry, 2002, Cytotoxic T lymphocytes: all roads lead to death, Nat Rev Immunol, 2, 401, 10.1038/nri819
Majno, 1995, Apoptosis, oncosis, and necrosis. An overview of cell death, Am J Pathol, 146, 3
Proskuryakov, 2002, Necrosis is an active and controlled form of programmed cell death, Biochemistry (Mosc), 67, 387, 10.1023/A:1015289521275
Haworth, 1979, The Ca2+-induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site, Arch Biochem Biophys, 195, 460, 10.1016/0003-9861(79)90372-2
Hunter, 1979, The Ca2+-induced membrane transition in mitochondria. I. The protective mechanisms, Arch Biochem Biophys, 195, 453, 10.1016/0003-9861(79)90371-0
Marzo, 1998, Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis, Science, 281, 2027, 10.1126/science.281.5385.2027
Narita, 1998, Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria, Proc Natl Acad Sci U S A, 95, 14681, 10.1073/pnas.95.25.14681
Pastorino, 1998, The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition, J Biol Chem, 273, 7770, 10.1074/jbc.273.13.7770
Baines, 2005, Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death, Nature, 434, 658, 10.1038/nature03434
Basso, 2005, Properties of the permeability transition pore in mitochondria devoid of cyclophilin D, J Biol Chem, 280, 18558, 10.1074/jbc.C500089200
Nakagawa, 2005, Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death, Nature, 434, 652, 10.1038/nature03317
Schinzel, 2005, Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia, Proc Natl Acad Sci U S A, 102, 12005, 10.1073/pnas.0505294102
Ha, 1999, Poly (ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion, Proc Natl Acad Sci U S A, 96, 13978, 10.1073/pnas.96.24.13978
Waring, 2005, Redox active calcium ion channels and cell death, Arch Biochem Biophys, 434, 33, 10.1016/j.abb.2004.08.001
Chung, 2000, A common set of engulfment genes mediates removal of both apoptotic and necrotic cell corpses in C. elegans, Nat Cell Biol, 2, 931, 10.1038/35046585
Driscoll, 1991, The mec-4 gene is a member of a family of Caenorhabditis elegans genes that can mutate to induce neuronal degeneration, Nature, 349, 588, 10.1038/349588a0
Huang, 1994, Gene interactions affecting mechanosensory transduction in Caenorhabditis elegans, Nature, 367, 467, 10.1038/367467a0
Bano, 2005, Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity, Cell, 120, 275, 10.1016/j.cell.2004.11.049
Levine, 2004, Development by self-digestion: molecular mechanisms and biological functions of autophagy, Dev Cell, 6, 463, 10.1016/S1534-5807(04)00099-1
Shintani, 2004, Autophagy in health and disease: a double-edged sword, Science, 306, 990, 10.1126/science.1099993
Yue, 2003, Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor, Proc Natl Acad Sci U S A, 100, 15077, 10.1073/pnas.2436255100
Qu, 2003, Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene, J Clin Invest, 112, 1809, 10.1172/JCI20039
Aita, 1999, Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21, Genomics, 59, 59, 10.1006/geno.1999.5851
Liang, 1999, Induction of autophagy and inhibition of tumorigenesis by beclin 1, Nature, 402, 672, 10.1038/45257
Shimizu, 2004, Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes, Nat Cell Biol, 6, 1221, 10.1038/ncb1192
Pattingre, 2005, Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy, Cell, 122, 927, 10.1016/j.cell.2005.07.002
Weaver, 2005, Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death, Cancer Cell, 8, 7, 10.1016/j.ccr.2005.06.011
Bartek, 2003, Chk1 and Chk2 kinases in checkpoint control and cancer, Cancer Cell, 3, 421, 10.1016/S1535-6108(03)00110-7
Hayflick, 1961, The serial cultivation of human diploid cell strains, Exp Cell Res, 25, 585, 10.1016/0014-4827(61)90192-6
d’Adda di Fagagna, 2003, A DNA damage checkpoint response in telomere-initiated senescence, Nature, 426, 194, 10.1038/nature02118
Takai, 2003, DNA damage foci at dysfunctional telomeres, Curr Biol, 13, 1549, 10.1016/S0960-9822(03)00542-6
Robles, 1998, Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts, Oncogene, 16, 1113, 10.1038/sj.onc.1201862
Schmitt, 2002, A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy, Cell, 109, 335, 10.1016/S0092-8674(02)00734-1
te Poele, 2002, DNA damage is able to induce senescence in tumor cells in vitro and in vivo, Cancer Res, 62, 1876
Shay, 1991, A role for both RB and p53 in the regulation of human cellular senescence, Exp Cell Res, 196, 33, 10.1016/0014-4827(91)90453-2
Dimri, 1995, A biomarker that identifies senescent human cells in culture and in aging skin in vivo, Proc Natl Acad Sci U S A, 92, 9363, 10.1073/pnas.92.20.9363
Narita, 2003, Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence, Cell, 113, 703, 10.1016/S0092-8674(03)00401-X
Hainaut, 2000, p53 and human cancer: the first ten thousand mutations, Adv Cancer Res, 77, 81, 10.1016/S0065-230X(08)60785-X
Reed, 2005, Apoptosis-based therapies for hematologic malignancies, Blood, 106, 408, 10.1182/blood-2004-07-2761
Fischer, 2005, New approaches and therapeutics targeting apoptosis in disease, Pharmacol Rev, 57, 187, 10.1124/pr.57.2.6
Dias, 2002, Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides, Eur J Pharm Biopharm, 54, 263, 10.1016/S0939-6411(02)00060-7
Tolcher, 2005, A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer, Clin Cancer Res, 11, 3854, 10.1158/1078-0432.CCR-04-2145
Walensky, 2004, Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix, Science, 305, 1466, 10.1126/science.1099191
Oltersdorf, 2005, An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, 435, 677, 10.1038/nature03579
Olgiati, 1984, Gossypol inhibition of adenylate cyclase, Arch Biochem Biophys, 231, 411, 10.1016/0003-9861(84)90404-1
Poznak, 2001, Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial, Breast Cancer Res Treat, 66, 239, 10.1023/A:1010686204736
Becattini, 2004, Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L), Chem Biol, 11, 389, 10.1016/j.chembiol.2004.02.020
Li, 2004, A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death, Science, 305, 1471, 10.1126/science.1098231
Sun, 2004, Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site, J Med Chem, 47, 4147, 10.1021/jm0499108
Oost, 2004, Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer, J Med Chem, 47, 4417, 10.1021/jm040037k
Schimmer, 2004, Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity, Cancer Cell, 5, 25, 10.1016/S1535-6108(03)00332-5
Wang, 2004, Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors, J Biol Chem, 279, 48168, 10.1074/jbc.M405022200
Xie, 2001, Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer, Cancer Res, 61, 6795
Song, 2005, Antiangiogenic gene therapy: disruption of neovascular networks mediated by inducible caspase-9 delivered with a transcriptionally targeted adenoviral vector, Gene Ther, 12, 320, 10.1038/sj.gt.3302306
Debatin, 2004, Death receptors in chemotherapy and cancer, Oncogene, 23, 2950, 10.1038/sj.onc.1207558
Kelley, 2004, Targeting death receptors in cancer with Apo2L/TRAIL, Curr Opin Pharmacol, 4, 333, 10.1016/j.coph.2004.02.006
Wajant, 2005, Tumor therapeutics by design: targeting and activation of death receptors, Cytokine Growth Factor Rev, 16, 55, 10.1016/j.cytogfr.2004.12.001
Hersh, 1991, Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience, J Immunother, 10, 426, 10.1097/00002371-199112000-00006
Eggermont, 2003, Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy, Curr Oncol Rep, 5, 79, 10.1007/s11912-003-0091-x
Lienard, 1992, High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, J Clin Oncol, 10, 52, 10.1200/JCO.1992.10.1.52
Renard, 1994, Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha), Int J Cancer, 57, 656, 10.1002/ijc.2910570508
Walczak, 1999, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat Med, 5, 157, 10.1038/5517
Ashkenazi, 1999, Safety and antitumor activity of recombinant soluble Apo2 ligand, J Clin Invest, 104, 155, 10.1172/JCI6926
Kelley, 2001, Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety, J Pharmacol Exp Ther, 299, 31
Ashkenazi, 2002, Targeting death and decoy receptors of the tumour-necrosis factor superfamily, Nat Rev Cancer, 2, 420, 10.1038/nrc821
Ichikawa, 2001, Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity, Nat Med, 7, 954, 10.1038/91000
Chuntharapai, 2001, Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4, J Immunol, 166, 4891, 10.4049/jimmunol.166.8.4891
Kim, 2000, Molecular determinants of response to TRAIL in killing of normal and cancer cells, Clin Can Res, 6, 335
Wang, 2003, Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy, Proc Natl Acad Sci U S A, 100, 15095, 10.1073/pnas.2435285100
Keane, 1999, Chemotherapy augments TRAIL-induced apoptosis in breast cell lines, Cancer Res, 59, 734
Nagane, 2000, Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo, Cancer Res, 60, 847
Chinnaiyan, 2000, Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy, Proc Natl Acad Sci U S A, 97, 1754, 10.1073/pnas.030545097
Nebbioso, 2005, Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells, Nat Med, 11, 77, 10.1038/nm1161
Inoue, 2002, Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis, Int J Mol Med, 9, 521
Shetty, 2005, Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1, Mol Cell Biol, 25, 5404, 10.1128/MCB.25.13.5404-5416.2005
Meng, 2001, p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma, Exp Cell Res, 262, 154, 10.1006/excr.2000.5073
Kelly, 2004, Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas, Br J Cancer, 91, 164, 10.1038/sj.bjc.6601895
Suh, 1999, A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity, Cancer Res, 59, 336
Place, 2003, The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo, Clin Cancer Res, 9, 2798
Kim, 2002, An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis, J Biol Chem, 277, 22320, 10.1074/jbc.M202458200
Pedersen, 2002, The triterpenoid CDDO induces apoptosis in refractory CLL B cells, Blood, 100, 2965, 10.1182/blood-2002-04-1174
Ito, 2000, The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism, Cell Growth Differ, 11, 261
Stadheim, 2002, The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells, J Biol Chem, 277, 16448, 10.1074/jbc.M108974200
Suh, 2003, Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL, Leukemia, 17, 2122, 10.1038/sj.leu.2403112
Zou, 2004, c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells, Cancer Res, 64, 7570, 10.1158/0008-5472.CAN-04-1238
Hyer, 2005, Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells, Cancer Res, 65, 4799, 10.1158/0008-5472.CAN-04-3319
Bykov, 2002, Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database, Carcinogenesis, 23, 2011, 10.1093/carcin/23.12.2011
Foster, 1999, Pharmacological rescue of mutant p53 conformation and function, Science, 286, 2507, 10.1126/science.286.5449.2507
Vassilev, 2004, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2, Science, 303, 844, 10.1126/science.1092472
Li, 1999, Release of mitochondrial cytochrome C in both apoptosis and necrosis induced by beta-lapachone in human carcinoma cells, Mol Med, 5, 232, 10.1007/BF03402120
Tagliarino, 2001, Calcium is a key signaling molecule in beta-lapachone-mediated cell death, J Biol Chem, 276, 19150, 10.1074/jbc.M100730200
Salomon, 2000, Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F(0)F(1)-ATPase, Proc Natl Acad Sci U S A, 97, 14766, 10.1073/pnas.97.26.14766
Bai, 2003, Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo, J Biol Chem, 278, 35501, 10.1074/jbc.M302967200
Uehlinger, 2000, et al. 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells, J Photochem Photobiol B, 54, 72, 10.1016/S1011-1344(99)00159-1
Golab, 2003, Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor, J Biol Chem, 278, 407, 10.1074/jbc.M209125200
Miccoli, 1998, Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria, Cancer Res, 58, 5777
Fabris, 2001, Photosensitization with zinc (II) phthalocyanine as a switch in the decision between apoptosis and necrosis, Cancer Res, 61, 7495
Hsieh, 2003, Subcellular localization of Photofrin determines the death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic therapy: when plasma membranes are the main targets, J Cell Physiol, 194, 363, 10.1002/jcp.10273
Reiners, 2002, Release of cytochrome c and activation of pro-caspase-9 following lysosomal photodamage involves Bid cleavage, Cell Death Differ, 9, 934, 10.1038/sj.cdd.4401048
Chiu, 2001, Dissociation of mitochondrial depolarization from cytochrome c release during apoptosis induced by photodynamic therapy, Br J Cancer, 84, 1099, 10.1054/bjoc.2000.1714
Belzacq, 2001, Apoptosis induction by the photosensitizer verteporfin: identification of mitochondrial adenine nucleotide translocator as a critical target, Cancer Res, 61, 1260
Inanami, 1999, Effects of BAPTA-AM and forskolin on apoptosis and cytochrome c release in photosensitized Chinese hamster V79 cells, Photochem Photobiol, 70, 650, 10.1111/j.1751-1097.1999.tb08265.x
Chabner, 2006, Cancer Chemotherapy and Biotherapy: Principles and Practices
Murcia, 1997, Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells, Proc Natl Acad Sci U S A, 94, 7303, 10.1073/pnas.94.14.7303
Wang, 1997, PARP is important for genomic stability but dispensable in apoptosis, Genes Dev, 11, 2347, 10.1101/gad.11.18.2347
Bryant, 2005, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 434, 913, 10.1038/nature03443
Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445
Zong, 2004, Alkylating DNA damage stimulates a regulated form of necrotic cell death, Genes Dev, 18, 1272, 10.1101/gad.1199904
Lotze, 2005, High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal, Nat Rev Immunol, 5, 331, 10.1038/nri1594
Zhou, 2004, Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus, J Biol Chem, 279, 27320, 10.1074/jbc.M308650200
Mayer, 1999, Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen, Science, 286, 971, 10.1126/science.286.5441.971
Sakowicz, 2004, Antitumor activity of a kinesin inhibitor, Cancer Res, 64, 3276, 10.1158/0008-5472.CAN-03-3839
Tao, 2005, Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage, Cancer Cell, 8, 49, 10.1016/j.ccr.2005.06.003
Zhou, 2004, Targeting the checkpoint kinases: chemosensitization versus chemoprotection, Nat Rev Cancer, 4, 216, 10.1038/nrc1296
Gatei, 2003, Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation, J Biol Chem, 278, 14806, 10.1074/jbc.M210862200
Xiao, 2003, Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents, J Biol Chem, 278, 21767, 10.1074/jbc.M300229200
Graves, 2000, The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01, J Biol Chem, 275, 5600, 10.1074/jbc.275.8.5600
Wang, 2005, et al. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities, J Med Chem, 48, 3118, 10.1021/jm048989d
Sorensen, 2003, Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A, Cancer Cell, 3, 247, 10.1016/S1535-6108(03)00048-5
Syljuasen, 2004, Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation, Cancer Res, 64, 9035, 10.1158/0008-5472.CAN-04-2434
Jackson, 2000, An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage, Cancer Res, 60, 566
Braig, 2005, Oncogene-induced senescence as an initial barrier in lymphoma development, Nature, 436, 660, 10.1038/nature03841
Gryaznov, 2001, Telomerase inhibitors--oligonucleotide phosphoramidates as potential therapeutic agents, Nucleosides Nucleotides Nucleic Acids, 20, 401, 10.1081/NCN-100002314
Herbert, 2005, Lipid modification of GRN163, an N3‘-->P5‘ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition, Oncogene, 24, 5262, 10.1038/sj.onc.1208760
Dikmen, 2005, In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor, Cancer Res, 65, 7866, 10.1158/0008-5472.CAN-05-1215
Levine, 2005, Autophagy in cell death: an innocent convict?, J Clin Invest, 115, 2679, 10.1172/JCI26390
Kondo, 2005, The role of autophagy in cancer development and response to therapy, Nat Rev Cancer, 5, 726, 10.1038/nrc1692
Scarlatti, 2004, Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1, J Biol Chem, 279, 18384, 10.1074/jbc.M313561200
Boya, 2005, Inhibition of macroautophagy triggers apoptosis, Mol Cell Biol, 25, 1025, 10.1128/MCB.25.3.1025-1040.2005
Yamamoto, 1998, Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells, Cell Struct Funct, 23, 33, 10.1247/csf.23.33
Paglin, 2001, A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles, Cancer Res, 61, 439